

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10577470
	Filing Date		2007-01-11
	First Named Inventor	Matthews	
	Art Unit	1626	
	Examiner Name	Kamal A. Saeed	
	Attorney Docket Number	007500.00007	

U.S.PATENTS							Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	4591589		1986-05-27	GASC et al.			
	2	7276505		2007-10-02	MATTHEWS			
If you wish to add additional U.S. Patent citation information please click the Add button.							Add	
U.S.PATENT APPLICATION PUBLICATIONS							Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Published Application citation information please click the Add button.							Add	
FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	97/34893	WO		1997-09-25	Astra Pharmaceuticals Ltd, and Astra Aktiebolag		<input type="checkbox"/>
	2	99/00391	WO		1999-01-07	Merck Sharp & Dohme Limited		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10577470
Filing Date	2007-01-11
First Named Inventor	Matthews
Art Unit	1626
Examiner Name	Kamal A. Saeed
Attorney Docket Number	007500.00007

3	2004/048378	WO		2004-06-10	Active Biotech AB		<input type="checkbox"/>
4	2004/055014	WO		2004-07-01	Active Biotech AB		<input type="checkbox"/>
5	2004/081011	WO		2004-09-23	Avidex Limited		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button [Add](#)

NON-PATENT LITERATURE DOCUMENTS

[Remove](#)

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	APPEL & BROSSART, "Development of Novel Compounds to Treat Autoimmune and Inflammatory Diseases and Graft Versus Host Reactions," Endocrin. Metab. Immune Disord. Drug Targets No. 7, pp 93-97, 2007	<input type="checkbox"/>
	2	BRUMEANU et al., "Down-regulation of autoreactive T-cells by HMG CoA reductase inhibitors," Clin. Immunol. Vol. 119, pp 1-12, 2006	<input type="checkbox"/>
	3	CHITALE & MOOTS, "Abatacept: the first T lymphocyte co-stimulation modulator, for the treatment of rheumatoid arthritis," Expert. Opin. Biol. Ther., Vol 8, pp 115-122, 2008	<input type="checkbox"/>
	4	CHOY, "T Cells in Psoriatic Arthritis," Curr. Rheumatol. Rep. Vol. 6, pp 437-41, 2007	<input type="checkbox"/>
	5	COPE et al., "The central role of T cells in rheumatoid arthritis," Clin. Exp. Rheumatol., Vol. 25, pp S4-S11, 2007	<input type="checkbox"/>
	6	DUBEY et al., "Costimulatory requirements of naive CD4+ T cells. ICAM-1 or B7-1 can costimulate Naive CD4 T Cell Activation but Both Are Required for Optimum Response," J Immunol., Vol. 155, pp 45-57, 1995	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10577470
Filing Date	2007-01-11
First Named Inventor	Matthews
Art Unit	1626
Examiner Name	Kamal A. Saeed
Attorney Docket Number	007500.00007

7	GIMMI et al., "Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation," Immunology, Vol. 90, pp 6586-90, July 1993	<input type="checkbox"/>
8	KRISTENSEN et al., "The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review," Scand. J. Rheumatol., Vol. 36, pp 411-417, 2007	<input type="checkbox"/>
9	LINSLEY et al., "Binding of the B Cell Activation Antigen B7 to CD28 Costimulates T Cell Proliferation and Interleukin 2 mRNA Accumulation," J. Exp. Med. Vol. 173, pp 721-30, March 1991	<input type="checkbox"/>
10	MALLONE & ENDERT, "T Cells in the Pathogenesis of Type 1 Diabetes," Curr. Diab. Rep., Vol. 8, pp 101-06, 2008	<input type="checkbox"/>
11	SURESH et al., "Role of CD28-B7 Interactions in Generation and Maintenance of CD8 T Cell Memory," The Journal of Immunology, Vol. 167: pp 5565-5573, 2001	<input type="checkbox"/>
12	WEISS et al., "Role of CD28-B7 Interactions in Generation and Maintenance of CD8 T Cell Memory," Neuroimmunol. Vol. 191, pp 79-85, 2007	<input type="checkbox"/>
13	Medigene Press Release, "RhuDex(TM) Clinical Development to Continue Following Feedback from Regulatory Authorities," October 5, 2009	<input type="checkbox"/>
14	COLLINS et al., "The interaction properties of costimulatory molecules revisited," Immunity, Vol. 17, pp. 201-210, 2002	<input type="checkbox"/>
15	LENSCHOW et al., "CD28/B7 system of T cell costimulation," Annu. Rev. Immunol., Vol. 14, pp. 233-258, 1996	<input type="checkbox"/>
16	HUXLEY et al., "High-affinity small molecule inhibitors of T cell costimulation," Chem. Biol., Vol. 11, pp 1651-1658, 2004	<input type="checkbox"/>
17	SALOMON et al., "B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes; Immunity, Vol. 12, pp 431-440, 2000	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10577470
Filing Date	2007-01-11
First Named Inventor	Matthews
Art Unit	1626
Examiner Name	Kamal A. Saeed
Attorney Docket Number	007500.00007

18	WEST, "Solid state chemistry and its applications," Wiley & Sons, New York, book Chapter 10, pp 358-359, 1988	<input type="checkbox"/>
19	GRIESSER, "The Importance of Solvates," Polymorphism in the Pharmazuetical Industry, Chapter 8, pp 211-230, 2006	<input type="checkbox"/>
20	STRIETH et al., "Paclitaxel encapsulated in cationic liposomes increases tumor microvessel leakiness and improves therapeutic efficacy in combination with Cisplatin," Clin Cancer Res., Vol. 14, No. 14, pp 4603-4611, 2008	<input type="checkbox"/>
21	LUKES et al., "Oral feeding with pig peripheral lymphocytes decreases the xenogeneic delayed type hypersensitivity reaction in galactosyltransferase knockout mice," Abstract, Transplant Proc., Vol. 37, No. 8, pp 3327-3331, 2005	<input type="checkbox"/>
22	STRIETH et al., "Tumor-selective vessel occlusions by platelets after vascular targeting chemotherapy using paclitaxel encapsulated in cationic liposomes," Int J Cancer, Vol. 122, No. 2, pp 452-460, 2008	<input type="checkbox"/>
23	AMES & BULL, "Preparation of cinnoline-3, 4-dicarbonitrile and -dicarboxylic acid," Tetrahedron, Vol. 37, No. 14, pp 2489-2491, 1981	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.